ContractGenfit S.A. • December 17th, 2021 • Biological products, (no disgnostic substances)
Company FiledDecember 17th, 2021 IndustryGENFIT: Ipsen and GENFIT enter into exclusive licensing agreement for elafibranor, a Phase III asset evaluated in Primary Biliary Cholangitis, as part of a long-term global partnership